See more : Villars Holding S.A. (0QLJ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Lipella Pharmaceuticals Inc. (LIPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lipella Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TBS Holdings,Inc. (9401.T) Income Statement Analysis – Financial Results
- Reliq Health Technologies Inc. (RHT.V) Income Statement Analysis – Financial Results
- FoxWayne Enterprises Acquisition Corp. (FOXW) Income Statement Analysis – Financial Results
- KIZUNA HOLDINGS Corp. (7086.T) Income Statement Analysis – Financial Results
- Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.NS) Income Statement Analysis – Financial Results
Lipella Pharmaceuticals Inc. (LIPO)
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 449.62K | 184.16K | 259.35K | 961.68K | 694.75K |
| Cost of Revenue | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| Gross Profit | -2.59M | -2.36M | -1.20M | -14.28K | 11.86K |
| Gross Profit Ratio | -575.87% | -1,283.43% | -461.71% | -1.48% | 1.71% |
| Research & Development | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| General & Administrative | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Other Expenses | 0.00 | -45.00 | 57.09K | 0.00 | 0.00 |
| Operating Expenses | 2.16M | 2.77M | 2.18M | 1.02M | 748.54K |
| Cost & Expenses | 5.20M | 2.77M | 2.18M | 1.02M | 748.54K |
| Interest Income | 137.84K | 1.68K | 104.00 | 3.17K | 334.00 |
| Interest Expense | 10.85K | 9.61K | 6.83K | 7.97K | 8.39K |
| Depreciation & Amortization | 1.69K | 2.59M | 1.92M | 56.86K | 53.79K |
| EBITDA | -4.61M | -2.59M | 0.00 | -53.69K | 334.00 |
| EBITDA Ratio | -1,024.52% | -1,405.37% | -716.66% | -5.58% | -7.74% |
| Operating Income | -4.75M | -2.59M | -1.92M | -56.86K | -53.79K |
| Operating Income Ratio | -1,055.55% | -1,406.26% | -738.71% | -5.91% | -7.74% |
| Total Other Income/Expenses | 126.99K | -7.98K | 50.36K | -4.79K | -8.06K |
| Income Before Tax | -4.62M | -2.60M | -1.87M | -61.66K | -61.85K |
| Income Before Tax Ratio | -1,027.31% | -1,410.59% | -719.30% | -6.41% | -8.90% |
| Income Tax Expense | 0.00 | -1.63K | 6.73K | 4.79K | -53.79K |
| Net Income | -4.62M | -2.60M | -1.87M | -66.45K | -61.85K |
| Net Income Ratio | -1,027.31% | -1,409.71% | -721.89% | -6.91% | -8.90% |
| EPS | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| EPS Diluted | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
| Weighted Avg Shares Out (Dil) | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
How News Impacts Your Penny Stocks Portfolio
Penny Stocks To Buy? 4 To Watch Now After Big News
Source: https://incomestatements.info
Category: Stock Reports